Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CPB1 | P15086 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 5/20 | 0.41 |
| ▸ | CTSK | P43235 | 13/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6699865 | 1.00 | KMT2A (0.44) | KMT2AL3MBTL1CPB1CTSLCTSK | |
| SCHEMBL6698054 | 0.91 | KMT2A (0.43) | KMT2AL3MBTL1CPB1CTSLCTSK | |
| SCHEMBL6702928 | 0.91 | KMT2A (0.43) | KMT2AL3MBTL1CPB1CTSLCTSK | |
| SCHEMBL6704197 | 0.88 | KMT2A (0.42) | KMT2AL3MBTL1CPB1CTSLCTSK | |
| SCHEMBL6693712 | 0.83 | CPB1 (0.43) | KMT2AL3MBTL1CPB1CTSLADORA3 | |
| SCHEMBL6697354 | 0.81 | SYK (0.41) | KMT2AL3MBTL1CPB1CTSLCTSK | |
| SCHEMBL7092695 | 0.81 | CPB1 (0.42) | CPB1CTSLCTSK | |
| SCHEMBL7162370 | 0.81 | CPB1 (0.42) | CPB1CTSLCTSK | |
| SCHEMBL6696342 | 0.81 | KMT2A (0.48) | KMT2AL3MBTL1CPB1CTSLCTSK | |
| SCHEMBL6698061 | 0.80 | KMT2A (0.41) | KMT2AL3MBTL1CPB1CTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831096-B2 | Effective against both A and B forms of influenza; oral bioavailability | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| US-20040097471-A1 | Inhibitors of neuraminidases | ABBVIE INC. | 2004-05-20 | — | — | US | disclosed |
| US-6455571-B1 | ESPECIALLY, INFLUENZA NEURAMINIDASE. | ABBOTT LABORATORIES | 2002-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097471-A1 | Inhibitors of neuraminidases | NEU1, NEU2, NEU4 | KMT2A 3372/4885L3MBTL1 3963/4885CPB1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.